Optometrists in Plaquemine, LA Accepting Medicare
4 Optometrists found. Showing 1 - 4
 Roger F Shaw Iii, OD Optometrist Medicare: Medicare Enrolled Practice Location: 23855 Eden St, Plaquemine, LA 70764 Phone: 225-687-4190 Fax: 225-687-2000 |
 Dr. Ann Hardin Shaw, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 23855 Eden St, Plaquemine, LA 70764 Phone: 225-687-2026 Fax: 225-687-2000 |
 Southern Eye Centers Optometrist Medicare: Medicare Enrolled Practice Location: 23855 Eden St, Plaquemine, LA 70764 Phone: 225-687-2026 Fax: 225-687-2000 |
Dr. Adam Pickle, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 23855 Eden St, Plaquemine, LA 70764 Phone: 225-687-2026 |
News Archive
New brain-to-computer chip technology revolutionizes neurological therapy
By stimulating certain areas of the brain, scientists can alleviate the effects of disorders such as depression or Parkinson's disease. That's the good news. But because controlling that stimulation currently lacks precision, over-stimulation is a serious concern - losing some of its therapeutic benefits for the patient over time.
APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Gemcitabine HCI for Injection, USP, in the 2 g dosage strength. APP will launch this presentation of Gemcitabine immediately.
Findings offer potential significance to the recovery of walking after spinal cord injury
Researchers at the medical university Karolinska Institutet have created a genetically modified mouse in which certain neurons can be activated by blue light. Shining blue light on brainstems or spinal cords isolated from these mice produces walking-like motor activity. The findings, which are published in the scientific journal Nature Neuroscience, are of potential significance to the recovery of walking after spinal cord injury.
Positive results from DARA's DB959 Phase 1b study on type 2 diabetes
DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.
› Verified 1 days ago
Speech-Language Pathologists
Physical Therapists
Optometrists
Occupational Therapists
Chiropractors